Wells Fargo & Company Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $26.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective trimmed by Wells Fargo & Company from $29.00 to $26.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Other research analysts have also issued research reports about the company. The Goldman Sachs Group reaffirmed a “sell” rating and set a $19.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, January 12th. Needham & Company LLC decreased their price target on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Wolfe Research initiated coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 6th. They issued a “peer perform” rating on the stock. Cantor Fitzgerald reduced their target price on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Finally, Robert W. Baird boosted their target price on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Twelve research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.53.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $22.00 on Tuesday. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $31.17. The firm has a market capitalization of $2.78 billion, a P/E ratio of 70.97 and a beta of 0.31. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10. The company’s fifty day moving average price is $22.99 and its 200 day moving average price is $23.49.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same quarter last year, the company posted ($0.46) earnings per share. The business’s quarterly revenue was up 133.0% compared to the same quarter last year. As a group, sell-side analysts predict that Apellis Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 2,892 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $19.79, for a total value of $57,232.68. Following the transaction, the chief financial officer directly owned 104,188 shares in the company, valued at approximately $2,061,880.52. This represents a 2.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Caroline Baumal sold 1,882 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $19.79, for a total transaction of $37,244.78. Following the sale, the insider owned 89,324 shares of the company’s stock, valued at approximately $1,767,721.96. This trade represents a 2.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 57,973 shares of company stock worth $1,237,824 in the last quarter. Insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC grew its position in shares of Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares during the period. Jones Financial Companies Lllp lifted its holdings in shares of Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares during the period. Osaic Holdings Inc. boosted its position in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after acquiring an additional 1,570 shares during the last quarter. Allworth Financial LP grew its holdings in Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Apellis Pharmaceuticals during the third quarter worth approximately $64,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS from Neutral to Buy, citing a stronger-than-expected launch trajectory for the company’s newly approved kidney-disease therapy and assigning a $28 price target — signaling notable upside if commercial momentum continues. Apellis upgraded at BofA on launch trajectory for kidney disease therapy
• Positive Sentiment: An analyst note argues Apellis’s current valuation understates Empaveli’s (the newly approved rare-kidney-disease drug) revenue potential after early uptake, supporting a re-rating if prescriptions and payor access scale. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (reducing upside expectations) but kept an Overweight stance — a mixed institutional signal that still leaves the company supported by some buy-side analysts. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, which is neutral for near-term flows and may cap upside for investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: A cluster of insider sales on Jan. 20 (including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and other officers) has been disclosed via Form 4 filings — a coordination of sales that can hurt sentiment even if sales are routine diversification. See CEO filing for details. CEO Cedric Francois Form 4

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.